Wuxi Biologics ADR reports FY results

Wuxi Biologics ADR press release ( OTCPK:WXXWY ): FY revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.

1% YoY. Diluted EPS slightly increased by 1.3% to RMB 0.



78. Adjusted EBITDA grew 14.4% YoY to RMB7,999.

3 million and adjusted profit increased.